Kalaris Therapeutics Inc (KLRS)
Automate Your Wheel Strategy on KLRS
With Tiblio's Option Bot, you can configure your own wheel strategy including KLRS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KLRS
- Rev/Share 0.0
- Book/Share 0.0
- PB 0.0
- Debt/Equity 0.0
- CurrentRatio 0.8455
- ROIC 22.1084
- MktCap 61717920.0
- FreeCF/Share 0.0
- PFCF -4.3672
- PE 0.0
- Debt/Assets 0.0
- DivYield 0
- ROE 0.3905
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | KLRS | Leerink Partners | -- | Outperform | -- | $20 | May 7, 2025 |
| Initiation | KLRS | William Blair | -- | Outperform | -- | -- | April 8, 2025 |
News
Bernstein Liebhard LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of AlloVir, Inc. Securities
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, June 05, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that the United States District Court for the District of Massachusetts has approved the following announcement of a proposed class action settlement that would benefit purchasers of AlloVir, Inc. securities (NASDAQ: KLRS):
Read More
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference.
Read More
Kalaris to Participate at Stifel Ophthalmology Forum
Published: May 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
PALO ALTO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will participate at an upcoming Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum.
Read More
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee
Published: April 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growth Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growth
Read More
About Kalaris Therapeutics Inc (KLRS)
- IPO Date 2020-07-30
- Website https://kalaristx.com/
- Industry Biotechnology
- CEO Mr. Andrew Oxtoby
- Employees 14